More than 50,000 cancer patients worldwide have received radiotherapy treatment with the aid of VISICOIL fiducial markers, radiopharmaceutical provider Ion Beam Applications (IBA) announced last week in Geneva at the European Society for Radiotherapy and Oncology's (ESTRO) forum.
The flexible helically wound gold marker is implanted into a patient's tumor volume to enable that a precise treatment radiation therapy dose is delivered based on image-guided patient setup.
